<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02025829</url>
  </required_header>
  <id_info>
    <org_study_id>01CH2013</org_study_id>
    <nct_id>NCT02025829</nct_id>
  </id_info>
  <brief_title>IL-17 Neutrophils in CF Lung Inflammation</brief_title>
  <official_title>The Role of IL-17 Neutrophils in CF Lung Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether IL-17 polymorphonuclear leukocytes (PMNs)
      are central to the disease pathology in CF. This will be determined by demonstrating that
      IL-17 PMNs are present in the CF airway, correlate with lung function measures, and decrease
      in patients being treated with IV antibiotics for a pulmonary exacerbation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of two parts which will be conducted in parallel. In the first part of
      the study, 14 subjects will be recruited for the Clinically Stable Cohort. Subjects will be
      asked to provide 1 gm of expectorated sputum and 40-ml of blood. A cell count and
      differential will be performed on the sputum followed by analysis for IL-17 PMNs by
      fluorescence-activated cell sorter (FACS). IL-17 PMNs also will be isolated by running the
      remainder of the cell pellet through a column of magnetic beads designed for this purpose.
      These neutrophils will be lysed and intracellular cytokines determined. Sputum supernatants
      will be stored frozen until analyzed for the presence of IL-1β, IL-6, IL-8, IL-17A, TGF-β,
      TNF-α, and neutrophil elastase. Clinical data will be captured from the subject's clinical
      outpatient visit including lung function measures and clinical culture results. IL-17 PMNs
      will be correlated with lung function measures and inflammatory mediators at baseline.

      In the second part of this study, 10 subjects will be recruited for the Exacerbation Cohort.
      Subjects will provide at least 1 gram of expectorated sputum and 40-ml of blood within 72
      hours of hospital admission. Sputum and blood will be processed and analyzed as described
      above. Sputum and blood also will be obtained at the end of treatment (within 72 hours of
      completion of IV antibiotics) when the subject is at his or her baseline as determined by the
      managing physician. Clinical data will be captured from the subject's hospitalization records
      including lung function measures and clinical culture results.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Sputum IL-17 Neutrophils</measure>
    <time_frame>End of Treatment, two weeks. Samples will be obtained from each study volunteer at the beginning of IV antibiotic treatment and at the completion of antibiotic treatment for a pulmonary exacerbation</time_frame>
    <description>In the Exacerbation/IV Antibiotics Cohort--Subjects will serve as their own controls. The percentage of neutrophils (in sputum) positive for IL-17 was determined by flow cytometry for each subject at the beginning and end of treatment for a pulmonary exacerbation. Sputum IL-17 neutrophil counts will be compared to the change in lung function (FEV1) as determined by spirometry (American Thoracic Society standards).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sputum Inflammatory Mediators: IL-1β, IL-6, IL-8, IL-17A, TGF-β, TNF-α, and Neutrophil Elastase</measure>
    <time_frame>Samples will be obtained at one outpatient clinic visit during the next calendar year</time_frame>
    <description>In the Clinically Stable Cohort--Measurement of sputum inflammatory mediators: IL-1β, IL-6, IL-8, IL-17A, TGF-β, TNF-α, and neutrophil elastase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Inflammatory Mediators: IL-1β, IL-6, IL-8, IL-17A, and Neutrophil Elastase</measure>
    <time_frame>End of Treatment, two weeks. Samples will be obtained from each study volunteer at the beginning of IV antibiotic treatment and at the completion of antibiotic treatment for a pulmonary exacerbation</time_frame>
    <description>In the Exacerbation/IV Antibiotics Cohort--Measurement of sputum inflammatory mediators by multiplex assay for IL-1β, IL-6, IL-8, and IL-17A. Neutrophil elastase determined by colorimetric assay. Measurements at the beginning of IV antibiotic treatment and after 2 weeks antibiotic treatment for a pulmonary exacerbation</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">14</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Clinically Stable</arm_group_label>
    <description>Patients with cystic fibrosis and are clinically stable, 10 subjects with one copy of F508del and 4 subjects with at least one copy of G551D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exacerbation</arm_group_label>
    <description>Patients with cystic fibrosis admitted for treatment of a pulmonary exacerbation with IV antibiotics, 10 subjects with one copy of F508del</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      peripheral white cells, serum, sputum white cells, sputum supernatants
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients seen in the cystic fibrosis outpatient clinic (Clinically Stable Cohort) and
        inpatient unit (Exacerbation/IV Antibiotics Cohort) of Cystic Fibrosis Center in Cleveland,
        OH (Rainbow Babies and Children's Hospital/University Hospitals Case Medical Center)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Both Cohorts: ≥ 18 &lt; 50 years of age

          -  For Both Cohorts: Must have a documented diagnosis of CF (positive sweat chloride ≥60
             milliequivalents (mEq)/liter, by pilocarpine iontophoresis) and/or a genotype with two
             identifiable mutations consistent with CF accompanied by one or more clinical features
             with the CF) phenotype

          -  For Both Cohorts: Chronically infected with P. aeruginosa defined by 2 positive
             cultures in the past year or 3 in the last two years

          -  For Both Cohorts: Ability to expectorate mucus

          -  For Both Cohorts: Ability to provide written informed consent

          -  For Clinically Stable Cohort: 4 subjects with one copy of G551D

          -  For Clinically Stable Cohort: 10 subjects who do not have G551D, they must have one
             copy of F508del

          -  For Clinically Stable Cohort: CF subjects must have a baseline FEV1 percent predicted
             &gt; 50% (in the last year, obtained from medical record)

          -  For Clinically Stable Cohort: Clinically stable: free of any acute illness for &gt;14
             days

          -  For Clinically Stable Cohort: Must have performed spirometry for clinical purposes at
             that clinical visit

          -  For Clinically Stable Cohort: Must have a sputum culture sent to the clinical lab for
             clinical purposes at the time of the study visit

          -  For Clinically Stable Cohort: Have not been prescribed any new systemic antibiotics
             for the 14 days prior to enrollment

          -  For Exacerbation/IV Antibiotics Cohort: One copy of F508del

          -  For Exacerbation/IV Antibiotics Cohort: Must have a doctor defined pulmonary
             exacerbation requiring treatment with IV antibiotics

          -  For Exacerbation/IV Antibiotics Cohort: Must have performed spirometry for clinical
             purposes within 72 hours of initiating IV antibiotics and within 72 hours of
             completing IV antibiotics

          -  For Exacerbation/IV Antibiotics Cohort: Must have a sputum culture sent to the
             clinical lab for clinical purposes within 72 hours of admission

        Exclusion Criteria:

          -  For Both Cohorts: Pregnancy (based on self-report)

          -  For Both Cohorts: Co-infection with Burkholderia cepacia complex organisms

          -  For Both Cohorts: Any condition that in the opinion of the subject or the subject's
             managing physician that would compromise that individuals ability to participate in
             these studies

          -  For Both Cohorts: Inability to tolerate the study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James F. Chmiel, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rainbow Babies and Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol. 2002 Aug;23(1):5-27. Review.</citation>
    <PMID>12162106</PMID>
  </reference>
  <reference>
    <citation>Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database Syst Rev. 2013 Jun 13;(6):CD001505. doi: 10.1002/14651858.CD001505.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;4:CD001505.</citation>
    <PMID>23765216</PMID>
  </reference>
  <reference>
    <citation>Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B; Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007 Nov 15;176(10):957-69. Epub 2007 Aug 29.</citation>
    <PMID>17761616</PMID>
  </reference>
  <reference>
    <citation>Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. Chest. 1999 Apr;115(4):1053-8.</citation>
    <PMID>10208207</PMID>
  </reference>
  <reference>
    <citation>Konstan MW. Ibuprofen therapy for cystic fibrosis lung disease: revisited. Curr Opin Pulm Med. 2008 Nov;14(6):567-73. doi: 10.1097/MCP.0b013e32831311e8. Review.</citation>
    <PMID>18812834</PMID>
  </reference>
  <reference>
    <citation>Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995 Mar 30;332(13):848-54.</citation>
    <PMID>7503838</PMID>
  </reference>
  <reference>
    <citation>Konstan MW, Schluchter MD, Xue W, Davis PB. Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med. 2007 Dec 1;176(11):1084-9. Epub 2007 Sep 13.</citation>
    <PMID>17872492</PMID>
  </reference>
  <reference>
    <citation>Chmiel JF, Konstan MW. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med. 2007 Jun;28(2):331-46. Review.</citation>
    <PMID>17467552</PMID>
  </reference>
  <reference>
    <citation>Taylor PR, Roy S, Leal SM Jr, Sun Y, Howell SJ, Cobb BA, Li X, Pearlman E. Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORγt and dectin-2. Nat Immunol. 2014 Feb;15(2):143-51. doi: 10.1038/ni.2797. Epub 2013 Dec 22. Erratum in: Nat Immunol. 2015 Feb;16(2):214.</citation>
    <PMID>24362892</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2013</study_first_submitted>
  <study_first_submitted_qc>December 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2014</study_first_posted>
  <results_first_submitted>December 6, 2016</results_first_submitted>
  <results_first_submitted_qc>February 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 24, 2017</results_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>James F. Chmiel</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>IL-17 neutrophils</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clinically Stable</title>
          <description>Patients with cystic fibrosis and are clinically stable, 10 subjects with one copy of F508del and 4 subjects with at least one copy of G551D</description>
        </group>
        <group group_id="P2">
          <title>Exacerbation</title>
          <description>Patients with cystic fibrosis admitted for treatment of a pulmonary exacerbation with IV antibiotics, 10 subjects with one copy of F508del</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clinically Stable</title>
          <description>Patients with cystic fibrosis and are clinically stable, 10 subjects with one copy of F508del and 4 subjects with at least one copy of G551D</description>
        </group>
        <group group_id="B2">
          <title>Exacerbation</title>
          <description>Patients with cystic fibrosis admitted for treatment of a pulmonary exacerbation with IV antibiotics, 10 subjects with one copy of F508del</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Sputum IL-17 Neutrophils</title>
        <description>In the Exacerbation/IV Antibiotics Cohort--Subjects will serve as their own controls. The percentage of neutrophils (in sputum) positive for IL-17 was determined by flow cytometry for each subject at the beginning and end of treatment for a pulmonary exacerbation. Sputum IL-17 neutrophil counts will be compared to the change in lung function (FEV1) as determined by spirometry (American Thoracic Society standards).</description>
        <time_frame>End of Treatment, two weeks. Samples will be obtained from each study volunteer at the beginning of IV antibiotic treatment and at the completion of antibiotic treatment for a pulmonary exacerbation</time_frame>
        <population>Regarding &quot;Clinically Stable&quot; Arm: Because very few neutrophils at the end of treatment for a pulmonary exacerbation were positive for IL-17, it was determined not to undertake studies examining sputum neutrophils during periods of clinical stability.</population>
        <group_list>
          <group group_id="O1">
            <title>Begining of Exacerbation</title>
            <description>Study volunteer at the beginning of IV antibiotic treatment for a pulmonary exacerbation</description>
          </group>
          <group group_id="O2">
            <title>End of Exacerbation</title>
            <description>Study volunteer at the completion of 2 weeks IV antibiotic treatment for a pulmonary exacerbation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sputum IL-17 Neutrophils</title>
          <description>In the Exacerbation/IV Antibiotics Cohort--Subjects will serve as their own controls. The percentage of neutrophils (in sputum) positive for IL-17 was determined by flow cytometry for each subject at the beginning and end of treatment for a pulmonary exacerbation. Sputum IL-17 neutrophil counts will be compared to the change in lung function (FEV1) as determined by spirometry (American Thoracic Society standards).</description>
          <population>Regarding &quot;Clinically Stable&quot; Arm: Because very few neutrophils at the end of treatment for a pulmonary exacerbation were positive for IL-17, it was determined not to undertake studies examining sputum neutrophils during periods of clinical stability.</population>
          <units>% of neutrophils positive for IL-17</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" spread="23"/>
                    <measurement group_id="O2" value="4" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Inflammatory Mediators: IL-1β, IL-6, IL-8, IL-17A, TGF-β, TNF-α, and Neutrophil Elastase</title>
        <description>In the Clinically Stable Cohort--Measurement of sputum inflammatory mediators: IL-1β, IL-6, IL-8, IL-17A, TGF-β, TNF-α, and neutrophil elastase</description>
        <time_frame>Samples will be obtained at one outpatient clinic visit during the next calendar year</time_frame>
        <population>Data not collected and will never be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Clinically Stable Cohort</title>
            <description>Clinically stable subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Inflammatory Mediators: IL-1β, IL-6, IL-8, IL-17A, TGF-β, TNF-α, and Neutrophil Elastase</title>
          <description>In the Clinically Stable Cohort--Measurement of sputum inflammatory mediators: IL-1β, IL-6, IL-8, IL-17A, TGF-β, TNF-α, and neutrophil elastase</description>
          <population>Data not collected and will never be analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Inflammatory Mediators: IL-1β, IL-6, IL-8, IL-17A, and Neutrophil Elastase</title>
        <description>In the Exacerbation/IV Antibiotics Cohort--Measurement of sputum inflammatory mediators by multiplex assay for IL-1β, IL-6, IL-8, and IL-17A. Neutrophil elastase determined by colorimetric assay. Measurements at the beginning of IV antibiotic treatment and after 2 weeks antibiotic treatment for a pulmonary exacerbation</description>
        <time_frame>End of Treatment, two weeks. Samples will be obtained from each study volunteer at the beginning of IV antibiotic treatment and at the completion of antibiotic treatment for a pulmonary exacerbation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Begining of Exacerbation</title>
            <description>Study volunteer at the beginning of IV antibiotic treatment for a pulmonary exacerbation</description>
          </group>
          <group group_id="O2">
            <title>End of Exacerbation</title>
            <description>Study volunteer at the completion of 2 weeks IV antibiotic treatment for a pulmonary exacerbation</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Inflammatory Mediators: IL-1β, IL-6, IL-8, IL-17A, and Neutrophil Elastase</title>
          <description>In the Exacerbation/IV Antibiotics Cohort--Measurement of sputum inflammatory mediators by multiplex assay for IL-1β, IL-6, IL-8, and IL-17A. Neutrophil elastase determined by colorimetric assay. Measurements at the beginning of IV antibiotic treatment and after 2 weeks antibiotic treatment for a pulmonary exacerbation</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1b (pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2313" spread="1452"/>
                    <measurement group_id="O2" value="757" spread="782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 (pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" spread="26"/>
                    <measurement group_id="O2" value="37" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8 (pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5785" spread="859"/>
                    <measurement group_id="O2" value="3428" spread="2604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17 (pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302" spread="185"/>
                    <measurement group_id="O2" value="147" spread="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophil elastase activity (pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195" spread="45"/>
                    <measurement group_id="O2" value="53" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Clinically Stable</title>
          <description>Patients with cystic fibrosis and are clinically stable, 10 subjects with one copy of F508del and 4 subjects with at least one copy of G551D</description>
        </group>
        <group group_id="E2">
          <title>Exacerbation</title>
          <description>Patients with cystic fibrosis admitted for treatment of a pulmonary exacerbation with IV antibiotics, 10 subjects with one copy of F508del</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. James Chmiel</name_or_title>
      <organization>University Hospitals Cleveland Medical Center</organization>
      <phone>216-844-3267</phone>
      <email>James.Chmiel@uhhospitals.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

